• Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma 

      Mastrella, Giorgia; Hou, Mengzhuo; Li, Min; Stöcklein, Veit M.; Zdouc, Nina; Volmar, Marie N.M.; Miletic, Hrvoje; Reinhard, Sören; Herold-Mende, Christel C.; Kleber, Susanne; Eisenhut, Katharina; Gargiulo, Gaetano; Synowitz, Michael; Vescovi, Angelo L.; Harter, Patrick N.; Penninger, Josef M.; Wagner, Ernst; Mittelbronn, Michel; Bjerkvig, Rolf; Hambardzumyan, Dolores; Schüller, Ulrich; Tonn, Jörg Christian; Radke, Josefine; Glass, Rainer; Kälin, Roland E. (Peer reviewed; Journal article, 2019)
      Antiangiogenic therapy of glioblastoma (GBM) with bevacizumab, a VEGFA-blocking antibody, may accelerate tumor cell invasion and induce alternative angiogenic pathways. Here we investigate the roles of the proangiogenic ...